EDN1 and Other metabolic disease: Although targeting ET-1-stimulated signaling pathways may offer a promising therapeutic strategy for fat cell-related metabolic disorders, clinical trials or extended mechanistic analyses for optimizing pathway-specific inhibitors and developing integrative treatment regimens to achieve sustainable metabolic health improvements still require further thorough studies.